Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome


YAZICI O., Ucar G., SÜTCÜOĞLU O., Turhal N. S. , Yildiz B., Karamouzis M., ...More

CURRENT MEDICAL RESEARCH AND OPINION, vol.38, no.4, pp.579-586, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 4
  • Publication Date: 2022
  • Doi Number: 10.1080/03007995.2022.2037848
  • Journal Name: CURRENT MEDICAL RESEARCH AND OPINION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Public Affairs Index
  • Page Numbers: pp.579-586
  • Keywords: Colorectal cancer, Greece, Turkey, panitumumab, cetuximab, bevacizumab, 1ST-LINE TREATMENT, OPEN-LABEL, BEVACIZUMAB, PHASE, FLUOROURACIL, MULTICENTER, PANITUMUMAB, LEUCOVORIN, CETUXIMAB, THERAPY
  • Gazi University Affiliated: Yes

Abstract

Objective The successful results obtained in trials may not necessarily translate into prolonged survival of metastatic colorectal cancer (mCRC) patients in real life. This multinational registry study aimed to evaluate the real-life data effecting the survival of patients with mCRC. Methods This is a multinational, retrospective registry study. Turkish and Greek mCRC patients diagnosed between 2005 and 2012, with at least 3 years of follow-up data or who died before 3 years of follow-up were included in the study. Results A total of 364 were included in the study. RAS and BRAF mutation rates were found to be 36% and 39%, respectively. As first-line therapy, 196 (54%) patients received bevacizumab and Anti-EGFR treatments in combination with chemotherapy. The objective response rate was 42% (n = 152) and 32% (n = 78) for 1(st) line and 2(nd) line treatments, respectively. While the median progression-free survival (PFS) with the 1(st) line treatment was 10 months, it was 7 months with the 2(nd) line treatments. In the total study population median PFS and overall survival (OS) were 10 (95% CI, 8.3-11.6) and 35 (95% CI, 30.7-39.2) months, respectively. In Turkish and Greek patients, median OS (36 months versus 29 months, p = .81) and PFS (10.2 versus 9.2, p = .42) were not different. In multivariate analysis, ECOG PS of >= 2 and having metastases in more than one region decreased overall survival (p = .002 and p = .003), it was found that wild RAS and BRAF mutations and second metastasectomy contributed to overall survival (p = .047 and p < .001). Conclusion In conclusion, it seems that the patient's performance status, tumor location, number of metastatic lesions at the time of diagnosis affect the prognosis of mCRC. Although access to molecular tests and first-line treatments differ between Greece and Turkey, no significant difference was found in survival times.